<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02517359</url>
  </required_header>
  <id_info>
    <org_study_id>SFT001</org_study_id>
    <secondary_id>2015-000440-41</secondary_id>
    <nct_id>NCT02517359</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of RV6153</brief_title>
  <official_title>A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Treatment With Single and Repeat Doses of Inhaled RV6153 in Healthy Subjects and Subjects With Stable Asthma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Respivert Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Respivert Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RV6153 is a new medicine being developed for possible treatment of asthma and smoking related&#xD;
      lung disease (also known as chronic obstructive pulmonary disease - COPD).&#xD;
&#xD;
      The main purpose of this study is to investigate the safety, tolerability, pharmacokinetics&#xD;
      and pharmacodynamics of single and repeat doses of RV6153&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Preset pharmacokinetic stopping criteria met at lower doses than expected.&#xD;
  </why_stopped>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of single and repeat doses assessed by incidence of treatment emergent adverse events</measure>
    <time_frame>Up to 29 days post final dose</time_frame>
    <description>Assessment of the number of adverse events reported by subjects following dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of single and repeat doses assessed by ECG (12-lead ECG)</measure>
    <time_frame>Up to 29 days post final dose</time_frame>
    <description>12-lead ECGs will be obtained using an ECG machine that automatically calculates heart rate and measures PR, QRS, QT, and QTcB/QTcF intervals. ECGs will be measured after resting for 5 minutes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of single and repeat doses assessed by vital sign measurement (blood pressure &amp; heart rate)</measure>
    <time_frame>Up to 29 days post final dose</time_frame>
    <description>Blood pressure heart rate will be assessed together using an automated device after resting for 5 minutes. Blood pressure will include systolic and diastolic measurements.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of single and repeat doses assessed by respiration rate</measure>
    <time_frame>Up to 29 days post final dose</time_frame>
    <description>Respiration rate will be measured after resting for 5 minutes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of single and repeat doses assessed by temperature</measure>
    <time_frame>Up to 29 days post final dose</time_frame>
    <description>Temperature will be measured orally</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of single and repeat doses assessed by spirometry</measure>
    <time_frame>Up to 29 days post final dose</time_frame>
    <description>Pulmonary function test measured from forced expiratory volume in 1 second (FEV1). Pulmonary function test will be repeated until three technically acceptable measurements have been made.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of single and repeat doses by assessment of clinical laboratory tests</measure>
    <time_frame>Up to 29 days post final dose</time_frame>
    <description>Clinical laboratory tests include haematology, clinical chemistry, urinalysis and additional parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamic (PD) effect of repeat doses of RV6153 assessed by sputum cell biomarkers</measure>
    <time_frame>Cohort 13 (subjects who smoke) only - assessments at screening and Days 1, 7 &amp; 14</time_frame>
    <description>Sputum samples will be collected to evaluate PD effects of repeat doses of RV6153 by assessment of phosphatidylinositol biphosphate (PIP2) and phosphatidylinositol triphosphate (PIP3).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma RV6153 levels</measure>
    <time_frame>Cohorts 1-9: Day 1, 10 samples, Days 2,8,15&amp;29, 1 sample per day; Cohorts 10, 12 &amp; 13: Days 1,7&amp;14, 10 samples per day, Days 2,8-13,1,21,28&amp;42, 1 sample per day; Cohort 11: Days 1,14&amp;28, 10 samples per day, Days 7,21,26,27,29,35,42&amp;56, 1 sample per day</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Sputum markers of inflammation</measure>
    <time_frame>Cohort 13 (subjects who smoke) only - assessments at screening and Days 1, 7 &amp; 14</time_frame>
    <description>Sputum samples will be collected to evaluate effects on inflammation by assessment of myeloperoxidase, IL-6, IL-8, TNF alpha and other exploratory parameters</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Asthma</condition>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Single dose, healthy volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>14 day repeat dose, healthy volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>28 day repeat dose, healthy volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>14 day repeat dose, asthma patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>14 day repeat dose, smokers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RV6153 single dose</intervention_name>
    <description>Safety and tolerability of single doses</description>
    <arm_group_label>Single dose, healthy volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RV6153 matching placebo single dose</intervention_name>
    <description>Safety and tolerability of single doses</description>
    <arm_group_label>Single dose, healthy volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RV6153 14 day repeat dose</intervention_name>
    <description>Safety and tolerability of repeat doses</description>
    <arm_group_label>14 day repeat dose, asthma patients</arm_group_label>
    <arm_group_label>14 day repeat dose, healthy volunteers</arm_group_label>
    <arm_group_label>14 day repeat dose, smokers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RV6153 matching placebo 14 day repeat dose</intervention_name>
    <description>Safety and tolerability of repeat doses</description>
    <arm_group_label>14 day repeat dose, asthma patients</arm_group_label>
    <arm_group_label>14 day repeat dose, healthy volunteers</arm_group_label>
    <arm_group_label>14 day repeat dose, smokers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RV6153 28 day repeat dose</intervention_name>
    <description>Safety and tolerability of repeat doses</description>
    <arm_group_label>28 day repeat dose, healthy volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RV6153 matching placebo 28 day repeat dose</intervention_name>
    <description>Safety and tolerability of repeat doses</description>
    <arm_group_label>28 day repeat dose, healthy volunteers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Cohorts 1 to 13 (all subjects)&#xD;
&#xD;
          -  Subject must be a man or woman aged between 18 to 65 years of age, inclusive: Women of&#xD;
             non-childbearing potential only - defined as being amenorrhoeic for greater than 1&#xD;
             year with an appropriate clinical profile or permanently sterilised. Men who are&#xD;
             willing and able to use suitable contraception methods listed in Section 4.5.1, from&#xD;
             the time of the first dose of study medication until 90 days after discharge from the&#xD;
             study.&#xD;
&#xD;
          -  A woman must have a negative serum β human chorionic gonadotropin (β-hCG) test at&#xD;
             screening and a negative urine pregnancy test at Day -1.&#xD;
&#xD;
          -  Subject must be willing and able to adhere to the prohibitions and restrictions&#xD;
             specified in this protocol&#xD;
&#xD;
          -  Each subject must sign an informed consent form (ICF)&#xD;
&#xD;
          -  Body weight ≥50 kg and BMI within the range 19-29 kg/m2 (inclusive).&#xD;
&#xD;
          -  Average QTcF &lt;450 msec at screening and Day -1 visits&#xD;
&#xD;
          -  Vital sign assessments within normal ranges.&#xD;
&#xD;
        Cohorts 1 to 11 and 13 (healthy volunteers and smokers only)&#xD;
&#xD;
          -  Healthy as determined by a physician, based on a full medical evaluation including&#xD;
             medical history, physical examination, laboratory tests.&#xD;
&#xD;
          -  Spirometry readings (FEV1 and FVC) to be ≥80% predicted value and FEV1/FVC ratio &gt;0.7&#xD;
             at screening.&#xD;
&#xD;
        Cohort 12 (asthma patients only)&#xD;
&#xD;
          -  Documented history of asthma, first diagnosed at least 6 months prior to the screening&#xD;
             visit.&#xD;
&#xD;
          -  Currently being treated with daily standard of care asthma therapy&#xD;
&#xD;
          -  Have a diagnosis of asthma confirmed at screening by bronchodilator reversibility.&#xD;
&#xD;
          -  Have stable asthma based on physician assessment at screening and prior to&#xD;
             randomisation, with no asthma exacerbation requiring augmentation of therapy in the 12&#xD;
             weeks prior to screening and no hospitalization or visit to accident and emergency for&#xD;
             asthma in the 12 months prior to screening.&#xD;
&#xD;
          -  Have a pre-bronchodilator forced expiratory volume in the first second (FEV1) ≥60% and&#xD;
             ≤85% of predicted normal value at screening.&#xD;
&#xD;
          -  Subject must be otherwise healthy on the basis of full medical evaluation performed at&#xD;
             screening.&#xD;
&#xD;
        Cohort 13 (smokers only)&#xD;
&#xD;
          -  Subjects who are current daily cigarette smokers.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Cohorts 1 to 13 (all subjects)&#xD;
&#xD;
          -  Upper or lower respiratory tract infection within 4 weeks of the screening visit and&#xD;
             prior to randomisation.&#xD;
&#xD;
          -  A positive pre-study hepatitis B surface antigen or positive hepatitis C antibody&#xD;
             result at screening.&#xD;
&#xD;
          -  Current or chronic history of liver disease, or known hepatic or biliary&#xD;
             abnormalities.&#xD;
&#xD;
          -  Positive test for alcohol or drugs of abuse.&#xD;
&#xD;
          -  Use of prescription medications within 14 days prior to the screening visit and agree&#xD;
             not to use prescription medications throughout the duration of the study.&#xD;
&#xD;
          -  Are taking over the counter (OTC) medications for 14 days prior to Screening visit and&#xD;
             agree to refrain from taking such medications throughout the study.&#xD;
&#xD;
          -  History of regular alcohol consumption within 6 months of the study&#xD;
&#xD;
          -  Definite or suspected history of drug or alcohol abuse within the previous 5 years.&#xD;
&#xD;
          -  A positive test for HIV antibody.&#xD;
&#xD;
          -  Received an experimental drug or used an experimental medical device within 3 months&#xD;
             or within a period less than five times the drug's half-life before the first dose of&#xD;
             the study drug is scheduled.&#xD;
&#xD;
          -  Allergy to any of the active or inactive ingredients (including lactose and milk&#xD;
             protein intolerance) in the study medication.&#xD;
&#xD;
          -  History of drug, or other allergy that would contraindicate their participation.&#xD;
&#xD;
          -  A disclosed history or one known to the Investigator, of significant non-compliance in&#xD;
             previous investigational studies or with prescribed medications.&#xD;
&#xD;
          -  Donated blood or blood products or had substantial loss of blood (more than 500 mL)&#xD;
             within 3 months before the first administration of study drug or intention to donate&#xD;
             blood or blood products during the study.&#xD;
&#xD;
          -  Subject is mentally or legally incapacitated.&#xD;
&#xD;
          -  Subject is an employee of the Sponsor or contract research organization (CRO), or a&#xD;
             relative of an employee of the Sponsor or CRO.&#xD;
&#xD;
          -  Unable or unwilling to undergo multiple venipuncture procedures or the subject has&#xD;
             poor access to veins suitable for cannulation.&#xD;
&#xD;
          -  Any other reason that the Investigator considers makes the subject unsuitable to&#xD;
             participate.&#xD;
&#xD;
        Cohorts 1 to 11 (healthy subjects only)&#xD;
&#xD;
          -  Any acute or chronic illness or clinically relevant abnormality identified on the&#xD;
             screening medical assessment.&#xD;
&#xD;
          -  The subject is a smoker or has smoked or used nicotine-containing products (including&#xD;
             e-cigarettes or other nicotine containing products) within the 6 months prior to&#xD;
             screening or has a smoking history of ≥5 pack years.&#xD;
&#xD;
          -  Positive urine cotinine test at the screening visit indicative of smoking or use of&#xD;
             tobacco or nicotine-containing products.&#xD;
&#xD;
        Cohort 12 (asthma patients only)&#xD;
&#xD;
          -  Has ever had an episode of life-threatening asthma defined as respiratory arrest,&#xD;
             intubation for asthma, or ICU admission for asthma&#xD;
&#xD;
          -  Has been hospitalized for greater than 24 hours due to asthma in the 5 years prior to&#xD;
             the study.&#xD;
&#xD;
          -  Has experienced an asthma exacerbation in the 3 months prior to screening (and prior&#xD;
             to randomisation) requiring management with systemic or injectable steroids.&#xD;
&#xD;
          -  Has uncontrolled (severe) asthma and/or use of the study prohibited asthma&#xD;
             medications.&#xD;
&#xD;
          -  The subject is a smoker (regular or irregular), or has smoked or used&#xD;
             nicotine-containing products (including e-cigarettes) within the 6 months prior to&#xD;
             screening (or a smoking history ≥10 pack years).&#xD;
&#xD;
          -  Positive urine cotinine test at the screening visit, and at Day -1, indicative of&#xD;
             smoking or use of tobacco or nicotine-containing products.&#xD;
&#xD;
        Cohort 13 (smokers only)&#xD;
&#xD;
          -  Any acute or chronic illness, including a diagnosis of COPD, or clinically relevant&#xD;
             abnormality identified on the screening medical assessment.&#xD;
&#xD;
          -  Subjects who are unable to produce a viable sputum sample at screening&#xD;
&#xD;
          -  Subjects whose primary consumption of tobacco is via methods other than cigarettes.&#xD;
             Primary methods of tobacco consumption that are excluded include, but are not limited&#xD;
             to pipes, cigars and e-cigarettes.&#xD;
&#xD;
          -  Urinary cotinine levels at screening &lt;30 nanograms (ng)/mL.&#xD;
&#xD;
          -  Subjects who have asthma or a history of asthma (except in childhood and which has now&#xD;
             remitted).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher O'Brien, MD, PhD, FCCP</last_name>
    <role>Study Director</role>
    <affiliation>Sponsor GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Manchester</city>
        <zip>M23 9QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nottingham</city>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>July 28, 2015</study_first_submitted>
  <study_first_submitted_qc>August 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2015</study_first_posted>
  <last_update_submitted>March 3, 2016</last_update_submitted>
  <last_update_submitted_qc>March 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

